Lomas David A
Wolfson Institute for Biomedical Research, Division of Medicine, University College London, London, United Kingdom.
Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S130-7. doi: 10.1513/AnnalsATS.201504-196KV.
Chronic obstructive pulmonary disease (COPD) is defined as airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with the inhalation of noxious gases, typically cigarette smoke. The protease-antiprotease paradigm suggests that the pathogenesis of COPD and emphysema is the result of an imbalance between enzymes that degrade the extracellular matrix within the lung and proteins that oppose this proteolytic activity. This review assesses the genetic evidence in support of protease-antiprotease imbalance in the pathogenesis of COPD. It also articulates why suppression of protease activity in alpha-1 antitrypsin deficiency may be insufficient to prevent the progression of COPD. Rather, alpha-1 antitrypsin deficiency may be better treated by small-molecules so reads molecules, RNA-silencing, and other strategies that target the protein misfolding and polymerization that cause the disease.
慢性阻塞性肺疾病(COPD)被定义为气流受限且不完全可逆。气流受限通常呈进行性发展,并与吸入有害气体(通常是香烟烟雾)有关。蛋白酶-抗蛋白酶范式表明,COPD和肺气肿的发病机制是肺内降解细胞外基质的酶与对抗这种蛋白水解活性的蛋白质之间失衡的结果。本综述评估了支持蛋白酶-抗蛋白酶失衡在COPD发病机制中的遗传证据。它还阐明了为什么在α-1抗胰蛋白酶缺乏症中抑制蛋白酶活性可能不足以阻止COPD的进展。相反,α-1抗胰蛋白酶缺乏症可能通过小分子、小分子RNA沉默和其他针对导致该疾病的蛋白质错误折叠和聚合的策略得到更好的治疗。